Hyperpolarized Xenon-129
Phase 3Small molecule
Hyperpolarized Xenon-129 is one of 53 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Zyvox
PfizerPhase 2
Biaxin
AbbViePhase 2
Lamprene
NovartisPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Myambutol
VVA Greater Los Angeles Healthcare System
Phase 2
Sirturo
WWim Janssens
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease1 trial
Biomarker1 trial
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Recruiting·—·Phase 2/3·NCT06856525·80 enrolled
Cystic Fibrosis1 trial
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
Active, not recruiting·—·Phase 4·NCT04467957·26 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyperpolarized Xenon-129. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details